baber/WOPTO huggingface dataset:
Patent NZ-289652-A (NZ)
Title: (r)-3-(1h-indol-3-yl)-1-[n-(2-methoxybenzyl)acetylamino]-2-[n-(2-(4-( piperidin-1-yl)piperidin-1-yl)acetyl)amino]propane dihydrochloride trihydrate; non-peptidyl tachykinin receptor antagonistic medicaments
Inventor: CHO STEPHEN SUNG-YONG
IPC: A61P13/02
Filed: 1995-06-30
Abstract: This invention provides the novel compound of the following formula   <CHEM> having the chemical name (R)-3-(1H-indol-3-yl)-1-ÄN-(2-methoxybenzyl)acetylaminoÜ-2-ÄN-(2-(4-(p iperidin-1-yl)piperidin-1-yl)acetyl)aminoÜpropane dihydrochloride trihydrate.
Patent NZ-289899-A (NZ)
Title: Peptide which binds to the p53 suppressor site of the MDM2 oncogene
Inventor: PICKSLEY STEVEN MICHAEL
IPC: A61K48/00
Filed: 1995-07-20
Abstract: The use of a compound for the manufacture of medicaments wherein the compound interferes with the binding between p53 and MDM2 or a protein having a p53 binding site analogous to that of MDM2, which compound comprises a p53 amino acid sequence motif having up to twenty eight amino acids and comprising the sequence FxxLW (Seq ID No: 4), wherein x is any amino acid, which is able to disrupt or prevent binding between p53 and MDM2, or functionally equivalent fragments thereof for use in medical treatment  comprising the inhibition of the growth of tumour cells which contain a human MDM2 gene amplification or over-expression.
Patent NZ-306829-A (NZ)
Title: Dessicant material included in a closed container
Inventor: HEKAL IHAD M
IPC: B29C45/16
Filed: 1996-04-17
Abstract: Shipping and storage container (01) having a body (12) and a cap (14) that together create an enclosure that is constructed from thermoplastic and that includes at least one insert (200) of high-concentration desiccant integrally molded therewith. The containers may be injection molded about a pre-formed insert is so that the insert is at least partially encased within the body of the container. Alternatively, the insert may be co-molded with the body of the container so that the two components are bonded together into one unitized and continuous body.
Patent NZ-324157-A (NZ)
Title: Conditionally replicating viral vectors and their use in treating HIV
Inventor: DROPULIC BORO
IPC: A61K31/7088
Filed: 1996-11-27
Abstract: A conditionally replicating viral vector, methods of propagating and selectively packaging, the vector, isolated molecules of specified nucleotide and amino acid sequences relevant to the vectors, a pharmaceutical compositions and host cells comprising the vectors and the use of a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and thus are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy.
Patent NZ-331435-A (NZ)
Title: Rescue position recording and signalling device activated by a dog tugging a tag or barking
Inventor: DANCE ADRIAN PETER
IPC: G01S5/00
Filed: 1998-08-19
Abstract: A device includes a switch that can be activated by a dog to cause the device to record and/or transmit information to identify the position of the device.  The switch may be activated by the dog pulling a tag (presumably using its teeth) or by the sound of the barking of the dog.  Positioning devices that have pull mechanisms such as bracelets, wrist bands, broaches, pendants and key chains and that may be pulled by a human to activate the switch are specifically disclaimed).  The device may be carried by trampers who may become disabled and found by a search dog who activates the device, or the dog that starts to bark when he finds the object of the search may carry the device.
Patent NZ-333083-A (NZ)
Title: Antibodies to the ED-B domain of fibronectin (FN), their construction and uses
Inventor: NERI DARIO
IPC: C12N15/09
Filed: 1997-05-23
Abstract: A process for the production of a specific binding member which is specific for and binds directly to the ED-B (foetal isoform of fibronectin) oncofoetal domain of fibronectin (FN) the process comprising i) expressing a library of molecules, which library includes specific binding members; and ii) isolating the specific binding member from the library. Once the peptide is screened for host bacterial cells are infected with positive clones, then subject the phage clones to a process of affinity maturation, repeat the steps above to select positive phage clones with improved affinity for antigen and infecting host cells with positive clones and purifying antibody molecules from the host cells. Further claimed is a specific binding member, which binds to all FNs containing ED-B after treatment of the FN with the protease thermolysin.
Patent NZ-334323-A (NZ)
Title: Herpesvirus saimiri as viral vector for genetic therapy
Inventor: MEREDITH DAVID MARK
IPC: C07K14/03
Filed: 1997-09-04
Abstract: A herpesvirus saimiri that has been genetically modified by mutating and/or deleting specific essential and non-essential genes. The mutation of ORF50 and/or ORF57 genes prevents viral replication in a human cell. The non-essential genes can represent sites for the insertion of heterologous genetic material, namely therapeutic genes.
Patent NZ-335610-A (NZ)
Title: Phenyl oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazole compounds useful as neuro-protective agents
Inventor: HEINZ LAWRENCE J
IPC: C07D233/64
Filed: 1997-10-06
Abstract: Compounds of formula (III) may be used to treat Alzheimer's disease, Parkinson's disease, amytrophic lateral sclerosis or cerebral trauma, or they may be used for inhibiting lipid peroxidation and preventing ischemia-induced cell damage.  In formula (III);  Ar is phenyl, pyridyl, tetrahydronaphthyl, benzofuranyl or chromanyl substituted with 0 to 2 substituents selected from the group of (C1-C6)alkyl, hydroxy and halo; and substituted with either:  (i) one or two substituents selected from the group consisting of O(CH2)tR6, C(=O)(CH2)nR6 and (C1-C6 alkyl)R6, (where R6 is NR7R8, morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl or optionally substituted piperazin-1-yl); and R7 and R8 are each individually hydrogen, (C1-C6)alkyl, (CH2)pOH, (CH2)pOC(=O)R9, (CH2 ) p-piperidyl, (CH2)pS(C1-C6)alkyl, (CH2)pS(C1-C6)alkyl, (CH2)pO(C1-C6)alkyl, (CH2)pS(=O)(C1-C6)alkyl, where R9 is (C1-C6)alkyl); or  (ii) two substituents which when taken together with the carbon atoms to which they are attached form a pyridyl or tetrahydropyridyl ring;  provided that when substituent pattern (i) is present, the phenyl or pyridyl group of Ar may additionally be substituted with two substituents which when taken together with the carbon atoms to which they are attached form a phenyl ring;  ---- represents a double or single bond; X is O or S; Y is CR5'R5, O or S, where R5' is H and R5 is H or OH, or R5 and R5' taken together are =0; Z is CH2 or N; R is H or (C1-C6)alkyl; R1 and R2 are each individually (C1-C6)alkyl, (C1-C6)alkoxy or phenyl; R3 is H or (C1-C6)alkyl or R3 and R4 taken together form a phenyl group with the ring to which they are attached; R4 is hydrogen or OH, or when Y is CHR5, R4 and R5 are each individually H or when taken together form a bond; m is an integer from 0 to 2, both inclusive; q is 0 or 1; n is an integer from 0 to 4 both inclusive; p is an integer from 1 to 6 both inclusive; and t is an integer from 1 to 4 both inclusive.
Patent NZ-336816-A (NZ)
Title: Prototype mould for blow-moulding hollow plastic containers and method of making same
Inventor: JOHNSTON RICHARD R
IPC: B29C33/04
Filed: 1999-07-19
Abstract: A prototype mould apparatus for blow moulding hollow plastics container comprises mould half portions 76, 76' and assembly of mould nest support components 52-74 which form a support pocket contoured complemental to that of the predetermined geometry of the mould halves.  Each mould half is assembled into the pocket of the associated one of the assembly of mould nest support components.  Each mould cavity 78, 78' in each half is generated using computer aided design to produce a geometric computer model of a container of desired contour.  The computer container model is then used to design and produce a software program for controlling a CNC machine to generate mould cavity for producing the container of desire contour and then use the software control program in a CNC machine and thereby machining a plurality of mould portions 76, 76'.  The mould nest components 52-74 have a cooling fluid manifold plate 56 with a fluid cooling channel.  The mould nest components include alignment pins 114-122 and individually cooperative alignment bushings 394, 396 mounted to the mould nest components independently of the mould halves operable for registering alignment of the mould halves in mould closed condition.
Patent NZ-505617-A (NZ)
Title: Peroxyacid compound use in odor reduction
Inventor: LOKKESMOE KEITH D
IPC: A61L9/01
Filed: 1998-12-30
Abstract: Disclosed is a process for the treatment of a plant fluid effluent containing odor compounds including an alkyl mercaptan or an alkyl thiol, an amine compound, ammonia, hydrogen sulfide and mixtures thereof by contacting the plant effluent in either a counter flow or concurrent flow process. In the process, the effluent is contacted with an aqueous solution comprising a peracid compound and optionally an essential oil. When contacted with the peracid, odor compounds in the effluent are oxidized and converted from the gaseous phase into a chemically modified highly aqueous soluble phase in the aqueous treatment. In this way, odor removal from the gas is preferred and odor compounds are efficiently transferred into the aqueous treatment solution. The use of such a process produces a significant improvement in odor quality index as measured by a conventional process using an expert panel when compared to conventional treatment methods.
Patent NZ-511131-A (NZ)
Title: Estrogen agonists/antagonists and cGMP elevators for treating female sexual dysfunction
Inventor: LEE ANDREW GEORGE
IPC: A61K31/40
Filed: 2001-04-17
Abstract: A method for treating female sexual dysfunction comprising administering to a female subject in need thereof, an effective amount of an estrogen agonist/antagonist and optionally co-administering an effective amount of a cyclic guanosine 3', 5'-monophosphate elevator. Also described are particular estrogen agonist/antagonists of varying formulas.
Patent NZ-511446-A (NZ)
Title: Short message service notification forwarded between multiple short message service centers
Inventor: LORELLO TIMOTHY J
IPC: H04W4/14
Filed: 1999-10-22
Abstract: A short message service (SMS) network allows more than one short message service center (SMSC) to service an individual subscriber with virtually no modification to the existing conventional network elements, e.g., the home location register (HLR) or the mobile switching center (MSC). In a disclosed embodiment, the HLR of the SMS network sends a notification, e.g., an SMS notification (SMSNOT) signal, to a predetermined one of the plurality of SMSCs in the SMS network when a subscriber becomes available to receive a pending short message from at least one of the plurality of SMSCs. Each of the plurality of SMSCs in turn delivers short messages to an intended subscriber, and then forwards the notification signal to another one of the SMSCs, until all of the SMSCs have delivered the respective pending short messages. The next SMSC to which the SMSNOT is forwarded may be fixedly determined, e.g., by network configuration. Moreover, the path for forwarding the SMSNOT signal may be reconfigured when one or more SMSCs are added to the SMS network. Alternatively, the forwarding path may be determined dynamically by the preceding SMSC in accordance with an intelligent rule based on parameters such as, for example, the type of short message(s) that was retained by the preceding SMSC, the address the intended subscriber, the type of intended subscriber, etc. The path may also be determined by a combination of fixed and dynamic selection. For instance, the selection of the next SMSC may normally be fixed, and upon an occurrence of a predetermined event, dynamic selection based on the intelligent rule(s) may be triggered
Patent NZ-514696-A (NZ)
Title: IL-8 receptor antagonists
Inventor: BENSON GREGORY MARTIN
IPC: A61P9/00
Filed: 2000-06-15
Abstract: This invention relates to novel compounds of Formula (I), and pharmaceutical compositions thereof, and methods of treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
Patent NZ-519150-A (NZ)
Title: Production of two alkali metal salts by a combined ion exchange and crystallisation process
Inventor: MATHIESEN FLEMMING
IPC: C01D9/04
Filed: 2000-12-01
Abstract: A process for producing an alkali metal nitrate and an alkali metal phosphate in the same process from a phosphate raw material and a nitrate raw material comprising the steps of: a) reacting the phosphate raw material with the nitrate raw material to provide an aqueous nitrophosphate feed, optionally followed by the separation of solid material, b) introducing the aqueous nitrophosphate feed into a first ion exchange step comprising an alkali metal-loaded cationic exchange resin for exchanging cations present in the feed with alkali metal ions present on the resin to obtain a stream enriched in alkali metal ions, c) subjecting the stream from step (b) to a first crystallisation under such conditions that an alkali metal nitrate is crystallised and separating the crystallised alkali metal nitrate from the mother liquor, d) introducing the mother liquor from step (c) into a second ion exchange step comprising an alkali metal-loaded cationic exchange resin for exchanging cations present in the mother liquor with alkali metal ions present on the resin to obtain a phosphate containing stream enriched in alkali metal ions, and e) subjecting the stream from step (d) to a second crystallisation under such conditions that an alkali metal phoshate is crystallised and separating the crystallised alkali metal phosphate from the mother liquor.
Patent NZ-520435-A (NZ)
Title: Process and composition for controlling fecal hair excretion and trichobezoar formation
Inventor: DAVENPORT GARY M
IPC: A23K1/14
Filed: 2001-01-05
Abstract: A process and composition for controlling fecal hair excretion and trichobezoar formation in animals such as cats and rabbits is provided and includes feeding the animal a composition comprising from about 10 to about 42 wt% crude protein, from about 4 to about 30 wt% fat, from about 1 to about 25 wt% total dietary fiber, and a supplemental fiber source. The supplemental fiber source is present in amounts which provide from about 1 to about 13 weight percent of supplemental total dietary fiber. The animal is maintained on the diet for a sufficient period of time to control fecal hair excretion and trichobezoar formation.
Patent NZ-522741-A (NZ)
Title: Method for promoting neovascularization using a TWEAK agonist and an angiogenic factor, such as fibroblast growth factor and VEGF
Inventor: JAKUBOWSKI ANIELA
IPC: A61K38/19
Filed: 2001-05-07
Abstract: Endothelial cell proliferation can be enhanced in an in vitro culture by adding a synergistically effective amount of TWEAK and an angiogenic factor. Also described is the use of a synergistically effective amount of TWEAK and an angiogenic factor in the manufacture of a medicament for enhancing angiogenic activity to promote neovascularization. Preferably the angiogenic factor is VEGF, hGF, bFGF, angiopoietin 2 or MCP-1 and the promotion of neovascularization is treat a myocardial ischemic condition, to promote wound healing and to promotes neovascularization of transplanted or grafted tissues or grans.
Patent NZ-529145-A (NZ)
Title: Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)- 2pyrimidine-amine and a chemotherapeutic agent
Inventor: BRUNS CHRISTIAN
IPC: A61K31/506
Filed: 2002-05-15
Abstract: Disclosed is a combination which comprises (a) N-{5- benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2- pyrimidine- amine and (b) a chemotherapeutic agent selected from antineoplastic agents selected from the group consisting of aromatase inhibitors, antiestrogens, topomerase I inhibitors, topomerase II inhibitors selected from the group consisting of epirubicin, idarubicin, nemorubicin, the anthraquinones mitoxonatrone and losoxantrone and teniposide, microtubule active agents selected from the group consisting of docetaxel, vinblastine, vinorelbine and discodermolide, alkylating agents selected from the group consisting of ifosfamide andmelphalan, antineoplastic antimetabolites selected from the group consisting of capecitabine, gemcitabine and edatrexate, platin compounds and compounds decreasing the protein kinase activity and further anti-angiogenic compounds selected from the group consisting of compounds decreasing the activity of the vascular endothelial growth factor (VEGF), of the platelet derived growth factor (PDGF) and protein kinase and of protein kinase C and antiangiogenic compounds having another mechanism for their activity, gonadrolin agonists, anti-androgens, bisphosphonates and trastuzumab and agents effective in treating acute or chronic transplant rejection, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
Patent NZ-532683-A (NZ)
Title: A sports bat including a handle, a blade with a hitting sweet spot, a toe, a pair of shoulders and one or more recesses
Inventor: SILLETT JONATHAN MARK
IPC: A63B59/08
Filed: 2002-10-10
Abstract: Disclosed is a sports bat comprising a handle and an elongate blade having a hitting sweet spot, the blade comprising a front playing face the majority of which is substantially planar across its face, an opposing rear surface, sides extending between the front face and rear surface, a toe and a pair of shoulders extending one each side of the handle to the sides, wherein the front playing surface comprises one or more recesses (29, 30) in at least one of the sides extending between the front face and rear surface of the blade.
Patent NZ-532958-A (NZ)
Title: Methods for esterifying hydroxyl groups in wood
Inventor: NEOGI AMAR N
IPC: B27K3/08
Filed: 2004-05-14
Abstract: Describes a method for esterifying wood, comprising: removing moisture from wood with a solvent or electromagnetic radiation to produce dried wood having less than about 8% water by weight; impregnating said dried wood with alkanoic anhydride; and heating impregnated wood with electromagnetic radiation to produce esterified wood having a degree of esterification from about 10% to about 25%.
Patent NZ-533133-A (NZ)
Title: Method for producing a recombinant polypeptide
Inventor: SCHORGENDORFER KURT
IPC: C12N15/85
Filed: 2002-11-26
Abstract: A method for producing a transformed eukaryotic host cell which expresses a recombinant polypeptide of interest comprises introducing into a eukaryotic host cell: (a) a first polynucleotide vector which comprises (i) a first nucleotide sequence which encodes a recombinant polypeptide of interest, and (ii) a second nucleotide sequence that encodes a selectable marker and is amplified when the host cell is contacted with a selection agent; and (b) a second polynucleotide vector having essentially the same nucleotide sequence as the first polynucleotide vector except that the second nucleotide sequence is replaced with a third nucleotide sequence which encodes a different selectable marker; (c) the first polynucleotide vector and the second polynucleotide are integrated into the genome of the host cell, with the proviso that if the eukaryotic host cell is human, it will be a transformed ex vivo human host cell.
Patent NZ-534760-A (NZ)
Title: Nutraceuticals for the treatment, protection and restoration of connective tissues
Inventor: SHEN BOJANG
IPC: C08B37/08
Filed: 2003-01-23
Abstract: A method for preparing a composition comprising connective tissue derived GAG-peptide complex and polypeptide comprises subjecting particles of connective tissue to enzyme mediated autolysis by contacting with an autolysis medium a divalent salt of pH of from about 2.5 to about 8.5 and at an effective temperature such that at least one GAG-peptide complex and at least one polypeptide are released substantially free of DNA, by the proteolytic actions of an endogenous enzyme(s) from within the tissue particles into the autolysis medium leaving residue tissue particles and recovering the GAG-peptide complex and polypeptide from the autolysis medium. The composition obtained by the method and connective tissue-derived chondroitin sulfate derived from the complex can be used in the manufacture of medicament from the treatment of inflammatory and degenerative tissue disorders such as rheumatoid arthritis and osteoarthritis, atherosclerosis, myocardial ischemia, degenerative and diabetic arteriopathies, thrombosis, embolisms, hyperlipideamis and cancer.
Patent NZ-536408-A (NZ)
Title: Absorbent article containing a skincare composition
Inventor: FARBROT ANNE
IPC: A61K8/02
Filed: 2003-05-26
Abstract: An absorbent article comprising a liquid permeable topsheet, a liquid impermeable backsheet, and an absorbent body enclosed therebetween, the article having a skincare composition applied on at least a portion thereof, so as to be transferable to the skin of the wearer, the composition being solid at 21°C and comprising: (a) 5-70% by weight of a component melting in the range 25 to 37°C, chosen from synthetic waxes, paraffins, fatty acid esters, polyhydroxy fatty acid esters, fatty alcohols, alkoxylated fatty acid esters, aloxylated fatty alcohols and mixtures of these compounds, and (b) 5-70% by weight of a component whose melting point is at least 5°C higher than the melting point of component (a), wherein (b) is chosen from paraffins, polyhydroxy fatty acid esters, fatty alcohols, fatty acids, alkoxylated derivatives of the fatty alcohols and fatty esters, and mixtures of these components, and (c) 5-75% by weight of a crystallisation accelerator component chosen from the group of partial glycerides, ethyleneglycol diesters and polymeric waxes, wherein the crystallisation accelerator has a melting point of 45-70°C and the composition comprises less than 5% by weight of water.
Patent NZ-536508-A (NZ)
Title: Automatic balancing device with two freely rotatable masses having viscous coupling
Inventor: JONES DAVID MICHAEL
IPC: F16F15/28
Filed: 2003-05-06
Abstract: Disclosed is an automatic balancing device for counterbalancing an out-of-balance mass present in a rotating body. The automatic balancing device (50) comprises a chamber (56) having an outer wall (54) and an axis (18), first and second counterbalancing masses (80a, 80b) constrained to move freely in a circular path about the axis (18) and within the chamber (56), and a viscous fluid (60) provided in the chamber (56) so as to provide viscous coupling between the outer wall (54) of the chamber (56) and each of the counterbalancing masses (80a, 80b). The counterbalancing masses (80a, 80b) are adapted and/or arranged such that, in use, the first counterbalancing mass (80a) leads the second counterbalancing mass (80b). Constraining means (94a, 94b) are provided so as to prevent the first counterbalancing mass (80a) from leading the second counterbalancing mass (80b) by more than substantially 180 DEG when the device is in use. This arrangement minimises the excursion of the rotating body at the critical speed. Such an arrangement has application particularly in the field of washing machines in which the position and size of the out-of-balance mass is unpredictable and there is a need to increase the speed of rotation of the body from a relatively low speed to a relatively high speed.
Patent NZ-536511-A (NZ)
Title: Nitrosated imidazopyridines
Inventor: BUHR WILM
IPC: A61K31/437
Filed: 2003-04-22
Abstract: Disclosed are nitrosated imidazopyridines of formula (1) where the substituents are as disclosed in the specification. Compounds of this type are useful in the treatment of gastrointestinal diseases.